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SPR negative signalEthR is a mycobacterial repressor that limits the bioactivation of ethionamide, a commonly used
anti-tuberculosis second-line drug. Several efforts have been deployed to identify EthR inhibitors
abolishing the DNA-binding activity of the repressor. This led to the demonstration that stimulating
the bioactivation of Eth through EthR inhibition could be an alternative way to ﬁght Mycobacterium
tuberculosis. We propose a new surface plasmon resonance (SPR) methodology to study the afﬁnity
between inhibitors and EthR. Interestingly, the binding between inhibitors and immobilized EthR
produced a dose-dependent negative SPR signal. We demonstrate that this signal reveals the afﬁnity of
small molecules for the repressor. The afﬁnity constants (KD) correlate with their capacity to inhibit
the binding of EthR to DNA. We hypothesize that conformational changes in EthR during ligand interac-
tion could be responsible for this SPR signal. Practically, this unconventional result opens perspectives
onto the development of an SPR assay that would at the same time reveal structural changes in the target
upon binding with an inhibitor and the binding constant of this interaction.Tuberculosis is one of the most frightening illnesses on the
planet. There were an estimated 8.6 million new TB1 cases in
2012, including 1.1 million cases among people infected with HIV,
and 1.3 million people died from TB that year [1]. Next to HIV infec-
tion, demographic factors, poor living conditions, and neglected TB
control in many countries caused this pandemic. There is an urgent
need for new drugs and new strategies to eliminate more efﬁciently
sensitive or drug-resistant strains. We have recently validated the
mycobacterial transcriptional repressor EthR as a new target to ﬁghttuberculosis. EthR belongs to the TetR/CamR family of transcriptional
regulators and negatively regulates the expression of ethA in Myco-
bacterium tuberculosis [2]. The ethA gene encodes a ﬂavin-containing
monooxygenase that catalyzes the bioactivation of ethionamide, one
of the most commonly used anti-TB second-line drugs [3,4].
We have shown that in vitro and in vivo allosteric inhibition of
the interaction between EthR and the ethA promoter with a drug-
like compound was able to improve ethionamide efﬁcacy, which
in mice allowed for a therapeutic dose reduction [5–7]. In the past
few years, several efforts have been made to identify and optimize
EthR inhibitors [5–10]. To that end, interactions between EthR and
synthetic inhibitors have been studied using a large panel of bio-
logical and biophysical assays such as X-ray crystallography [7],
thermal shift assay detecting the thermostabilization effect of the
ligand on the protein [8,11], and ﬁnally surface plasmon resonance
(SPR) [2,5–7].
Using the SPR biosensor assay, the interaction between biomol-
ecules immobilized on a sensor surface and biomolecules or small
chemical entities ﬂowing over the chip in an aqueous buffer is
quantiﬁed by measuring variations in refractive index. Interactions
on the gold surface of the biosensor chip between two partners in-
crease the electron density around the sensor surface and in most
cases induce positive changes in the refractive index, translated as
a real-time SPR signal called a sensorgram (resonance unit as func-
tion of time) [12]. SPR is an ideal tool to generate high-quality data
on the interactions between biomolecules, as well as between
small ligands and biomolecules. Direct binding assay based on
SPR presents many advantages: it is label-free, has a low target
consumption, and provides real time analysis and detection of
low-afﬁnity target binders [13].
As an efﬁcient tool to study inhibitors of EthR, we previously
designed a bioanalytical assay based on SPR. SPR was used to mea-
sure the capacity of inhibitors to disturb the interaction between
EthR and its DNA operator (DNA/EthR SPR methodology) [2,5–7].
Although very useful to quantify the capacity of EthR ligand to
inhibit the DNA binding function of EthR, this approach was
unsuitable for revealing the binding constants that drive the direct
interactions between EthR and the inhibitors, which allowed only
fragmentary comparisons between compounds. Then, to further
characterize our EthR inhibitors by accessing binding constants
(KD), we immobilized the transcriptional repressor EthR on a
CM5 carboxymethylated sensor chip and monitored the interac-
tion with EthR inhibitors in solution (ligand/EthR SPR methodol-
ogy). We report here an SPR assay focusing on the direct ligand/
transcriptional repressor interactions to compare chemical series
of new EthR inhibitors. This assay produced unconventional nega-
tive SPR signals that we demonstrate to be speciﬁc for the ligand/
protein interaction. We discuss the hypothesis that this signal
could be predictive of the allosteric structural changes undergone
during ligand/protein interaction and examine the implications
of this observation in the context of target-based drug screening.Materials and methods
SPR experiments were carried on a BIAcore 3000 instrument (GE
HealthCare). Thermal shift assay (TSA) experiments were per-
formed on a LightCycler 480 instrument (Roche). Research-grade
CM5, SA (streptavidin), and NTA (nitrilotriacetic acid) sensors were
purchased from GE HealthCare. HBS-EP (10 mM Hepes, 150 mM
NaCl, 3 mM EDTA, 0.005% surfactant P20) was purchased from GE
HealthCare and used with various sodium chloride concentrations.
All chemicals used (Tris–HCl, NaCl, EDTA, DTT (dithiothreitol), NHS
(N-hydroxysuccinimide), EDC (N-ethyl-N0-(3-diethylaminopro-
pyl)carbodiimide hydrochloride), ethanolamine, and Sypro orange)
were of the highest grade available commercially.
Plasmid construction and His6-EthR and His6-EthR-mutant expression
and puriﬁcationConstruction of plasmid pET-15b-ethR
The N-terminally hexahistidine-tagged EthR was produced in
Escherichia coli C41 (pET-15b-ethR) and puriﬁed as described. The
DNA coding for EthR was ampliﬁed by PCR using M. tuberculosis
H37Rv chromosomal DNA as template and oligonucleotides
O-183, 50-CATATGACCACCTCCGCGGCCAGT-30, and O-184, 50-GGAT
CCGAGCACCCCCGACCGAGT-30, as primers. The PCR product was
inserted into pCR2.1Topo (Invitrogen) to generate pCR2.1-ethR.
The EthR-encoding fragment was sequenced on both strands and
then isolated from pCR2.1-ethR by digestion with NdeI and BamHI
and inserted into pET-15b (Novagen), yielding pET-15b-ethR. This
plasmid encodes EthR containing an extra amino-terminal tag with
the following sequence: MGSSH6SSGLVPRGSHM.Construction of plasmid pET-15b-ethRG106W
Aﬁrst PCR productwas obtained by ampliﬁcation usingM. tuber-
culosis H37Rv chromosomal DNA as template and oligonucleotides
O-275 (50-AGGACCGTCCGCTGGCCGATA-30) and O-276 (50-AACA
CGTTGATCCAGGTGCGCCACA-30) as primers, thus introducing a
point mutation at codon 106 of ethR (underlined in oligonucleotide
O-276), resulting in the replacement of glycine 106 by a tryptophan
residue. This 216-bp fragmentwas used as a 50 primer in association
with oligonucleotide O-278 (50-GCTTCCTTTCGGGCTTTGTTAGCAG-
30) to amplify a 594-bp fragment, which was subsequently inserted
into PCRII-Topo (Invitrogen) to generate pCRIIethRG106W. The
275-bp SalI–SalI fragment of pET-15b-ethR [2] was then exchanged
for the equivalent fragment of pCRIIethRG106W to produce pET-
15b-ethRG106W. The orientation of the fragment was checked by
restriction digestion and the DNA sequence was conﬁrmed by
sequencing of the entire open reading frame.
Production and puriﬁcation of His6-EthR and mutant His6-EthRG106W
N-terminally hexahistidine-tagged EthR WT or G106W was
produced in E. coli C41 using the protein expression plasmids
pET-15b-ethR and pET-15b-ethRG106W, respectively, as previously
described [2]. Bacteria were grown in 100 ml LB broth to an
OD600 nm of 0.6–0.7. Isopropylthiogalactoside was then added to
a ﬁnal concentration of 1 mM and the culture was grown for 3 h.
The cells were harvested by centrifugation at 12,000g at 4 C,
resuspended in 10 ml of lysis buffer (50 mM Tris–HCl, 300 mM
NaCl, pH 7.5, 10 mM imidazole), and lysed by two passages at
6.2 MPa through a French press cell. After centrifugation
(20,000g, 25 min, 4 C), the supernatant was recovered and His6-
EthR or His6-EthRG106W was separated from the whole-cell lysate
by Ni–NTA agarose chromatography (Qiagen). After three washing
steps with lysis buffer, His6-tagged proteins were eluted from the
resin with 250 mM imidazole in lysis buffer, dialyzed overnight
against EthR buffer (10 mM Tris–HCl, 300 mM NaCl, pH 7.5,
1 mM DTT, 0.1 mM EDTA), and concentrated to 14 mg/ml for EthR
and 7 mg/ml for EthRG106W. Protein purity was controlled by Coo-
massie blue staining after SDS–PAGE on a 12% polyacrylamide gel.
Protein concentration was evaluated using the Bio-Rad protein as-
say kit. Puriﬁed proteins His6-EthR and His6-EthRG106W were stored
in EthR buffer at 4 C.
Production of biotinylated double-stranded DNA fragments
The 106-bp fragment overlapping the ethA-R intergenic region
(DNAetha-r) was obtained from M. tuberculosis H37Rv chromosomal
DNA using O-270, 50-CGGTCATGGATCCACGCTATCAAC-30, and
O-271, 50-biotin-CTGACTGGCCGCGGAGGTGGT-30. The biotinylated
double-stranded 113-bp-long irrelevant DNA fragment (+14 to
+127) of the E. coli bla gene was PCR ampliﬁed using oligonucleo-
tides O-343, 50-TTTCCGTGTCGCCCTTATTCC-30, and O-344, 50-CCAC
TCGTGCACCCAACTGAT-30, and pUC18 as substrate (DNAnonspeciﬁc).
The ampliﬁed biotinylated fragments were puriﬁed on a QiaQuick
column (Qiagen), cloned, and sequenced.
SPR assay for determining EthR/ligand afﬁnity
Immobilization of EthR and EthRG106W on CM5 sensor chip
All SPR experiments were performed at 25 C. Capture of EthR
and EthRG106W was performed on CM5 sensor chips with a carbo-
xymethylated dextran matrix using an HBS-EP running buffer
(10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfac-
tant P20). The chip was ﬁrst activated by injecting a fresh mixture
(35 ll, 50/50, v/v) of 0.1 mM NHS and 0.4 mM EDC at a ﬂow rate of
5 ll/min. Several 5-ll injections of EthR or EthRG106W, respectively
at 15 and 30 lg/ml, in 10 mM acetate buffer, pH 4.5, were per-
formed so as to reach the desired level of covalently attached
protein (1000, 2000, 4000, 7000, or 10000 resonance units (RU)).
Noncovalently bound esters were deactivated by injection of
35 ll of 1 M ethanolamine hydrochloride, pH 8.5, followed by a
surface wash with a 0.03% SDS solution.
Real-time binding experiment for EthR/ligand interaction on CM5
Binding experiments were performed with a constant ﬂow rate
of 20 ll/min using HBS-EP buffer (10 mM Hepes, 350 mM NaCl,
0.005% surfactant P20, 3 mM EDTA, 1% Me2SO) as the running buf-
fer. Experiments were performed on a CM5 sensor functionalized
with 4000 RU of EthRG106W on the reference ﬂow cell (F1) and with
the equivalent amount of EthR on the analysis ﬂow cell (F2). Li-
gands were injected at atleast six different concentrations over
both channels. The range of concentrations was selected from 0,
0.1, 0.33, 1, 3, 6, 9, 27, 60, 81, 121, 243 lM, depending on the sol-
ubility of the ligand (visual test in the running buffer) and on the
minimal concentration necessary to observe a signal. All experi-
ments were repeated at least three times and each concentration
was tested in triplicate. The ﬁnal sample concentration of Me2SO
was 1%. The samples were injected over 2, 5, 9, or 16 min. The
injection time was chosen so as to observe the equilibrium state
for at least two concentrations. As all the ligands were able to dis-
sociate from the protein during the course of the running buffer on
the surface, we avoided injection of a regeneration solution to pre-
serve the sensor chip. Dissociation times up to 20 min were applied
to recover the initial baseline level between injections of the vari-
ous ligands at increasing concentrations. This dissociation time
was increased as long as necessary for high-afﬁnity ligands such
as BDM41907 and BDM44831. The binding sensorgrams were ob-
tained from the subtraction F2F1.
Data analysis for KD determination
For all the ligands studied the KD was determined using the fol-
lowing method: the sensorgrams were analyzed using BIAevalua-
tion software version 4.0.1. As the software cannot interpret aN
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Fig.1. Negative SPR signals produced by BDM41907 injection onto an EthR-functionalized
conditions: HBS-EP running buffer (10 mM Hepes, 350 mM NaCl, 0.005% surfactant P20
time of 16 min. Sensorgrams were obtained after reference cell subtraction (F2–1). Chan
cell.negative sensorgram, the curves were mirrored by multiplication
of the data by 1. Subtraction of a blank sensorgram, obtained
by injecting ligand buffer, was performed before each series of
analysis to correct for bulk effect and other systematic artifacts.
The corresponding data were ﬁtted using all concentrations simul-
taneously and both association and dissociation curves were ﬁtted
simultaneously. For all ligands analyzed, the one-to-one Langmuir
model provided adequate ﬁtting. In the following equation, A rep-
resents the analyte in solution, B the protein immobilized, and AB
the complex formed by the interaction on the chip:
Aþ B !kon
koff
AB:
The adequateness of the ﬁt was judged by the values of the v2
(lower than 5% of the Rmax) and the randomness of residue distri-
bution. The association rate constant (kon) and the dissociation rate
constant (koff) were derived from the optimal binding model using
BIAevaluation software. The dissociation constant KD was calcu-
lated based on the ratio of koff/kon.KD calculated from RU values at the equilibrium state
For the ﬁt validation, some KD values were also extrapolated
from graph with the response (RU) at the equilibrium state as a
function of the ligand concentration. Normalization, ﬁt, and detec-
tion of the inﬂection point of the curves were performed using
GraphPad Prism 5.0. to determine KD values.SPR analysis of ligand/EthR interaction on NTA sensor chip
Analysis of ligand/EthR interaction on NTA was performed in
four steps using a 50 lM EDTA HBS-EP running buffer at 10 ll/
min: activation of the surface, immobilization of His6-EthR, injec-
tion of the ligand, and elimination of the protein from the surface.
Activation of the NTA surface was performed in channel F2 usingN
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nel 1 (F1) was immobilized with 2000 RU EthRG106W and used as the reference ﬂow
the standard protocol provided by BIAcore (GE HealthCare). Injec-
tion of 5 ll of a 500 lM NiCl2 solution was performed to load Ni2+
ions on the surface and activate the NTA sensor chip. Injection of
20 ll of a 150 nM solution of EthR in running buffer was performed
to achieve a signal of 2700 RU. Eight minutes after EthR immobili-
zation (necessary for baseline stabilization), the ligands were in-
jected over channels F1 and F2 during 4 min so as to observe the
equilibrium state. After 10 min of dissociation, the surface was
ﬂushed with 5 ll of solution W (10 mM Hepes, 150 mM NaCl,
0.35 M EDTA, 0.005% surfactant P20) to remove all protein from
the surface. Activation, immobilization, analysis, and regeneration
cycle were performed for each ligand analysis. The oriented cap-
ture of EthR on the surface of the NTA sensor chip allows slow
and continuous dissociation of the protein, resulting in a nonhori-
zontal baseline. To take this phenomenon into account, subtraction
from the same ﬂow cell of a buffer injection completed before li-
gand analysis was systematically performed. Using this technique,
we obtained horizontal baselines that allowed comparison of NTA-25
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Fig.2. Speciﬁcity of the negative SPR signal. Sensorgrams of BDM41160 (negative control)
sensor chip. Analytical conditions: HBS-EP running buffer; ﬂow, 20 ll/min; 2000 RU of
reference cell subtraction (F2–1). Channel 1 (F1) was immobilized with 2000 RU EthRG1and CM5 analysis. However, because of this continuous EthR disso-
ciation, NTA sensor chips were not used for KD determination.
SPR assay for determining the inhibition of EthR/DNA binding by
ligands
Immobilization of biotinylated double-stranded EthA promoter
On sensor chip SA with preimmobilized streptavidin, irrele-
vant and relevant DNA fragments were immobilized on channels
F1 and F2, respectively. The ﬁrst channel of the chip (F1) was
loaded with a 150 ng/ml biotinylated double-stranded 113-bp-
long irrelevant DNA fragment at a ﬂow rate of 10 ll/min to
obtain 75 RU stable binding to the streptavidin. The 106-bp bio-
tinylated ethA-R DNA intergenic region at 150 ng/ml was injected
through the second channel (F2) at a ﬂow rate of 10 ll/min to
reach the same 75-RU stable ﬁxation to the streptavidin. The
sensor chip was then washed with 0.03% SDS before protein
injection.400 500
e control)
s
Buffer 
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27 µM
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81 µM 
121 µM 
400 500
s
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06W and used as the reference ﬂow cell.
-25
-21
-17
-13
-9
-5
-1
3
0 100 200 300 400 500 600 700
BDM_41906RU
R
es
p.
 D
iff
.
sTime
Buffer 
0.3 µM
1 µM
3 µM
6 µM
27 µM
81 µM
243 µM
500 µM
O
H2N
N
N O N
S
HClBDM41160 
N
N O N
S
O
S
BDM31381 
N
N O N
N
S
O
F
F F
BDM41906 
Fig. 2 (continued)IC50 determination
Binding of EthR to the immobilized DNA was measured at
25 C in 10 mM Tris–HCl (pH 7.5), 200 mM NaCl, 0.1 mM EDTA,
1 mM DTT, and 1% Me2SO at a ﬂow rate of 20 ll/min. SA sensor
chips immobilized with 75 RU of speciﬁc and nonspeciﬁc DNA
fragments were used for the analysis. A speciﬁc interaction (SI)
between EthR and the 106-bp DNA fragment was deﬁned as the
signal difference between both channels (F2F1). Six different
concentrations, between 25.4 nM and 500 lM, were used for
IC50 determination. Successive dilutions of the initial compound
solution were performed in the binding buffer to obtain the de-
sired ﬁnal concentrations containing 1% in Me2SO, incubated
5 min at 37 C in the presence of 540 nM EthR, and injected over
the two channels at a ﬂow rate of 20 ll/min for 3 min. EthR to
DNA dissociation was achieved by ﬂowing buffer for 20 min on
the chip before the next binding measurement. SDS (0.03%) wash
was abolished because of low recovery of stable baseline. SI val-
ues were measured at the end of the injection period and allowed
to calculate each ligand inhibition percentage according to the
following ratio:
% Inhibition ¼ 100 SIEthR  SIEthRþcpd
 
=SIEthR
 
:
Percentages of inhibition were plotted as a function of the con-
centration of the compounds and IC50 values were determinedusing a sigmoidal dose–response (variable slope) model from
GraphPad Prism 5.0. The IC50 is the concentration of inhibitor that
causes 50% inhibition of EthR binding to DNA.Thermal shift assay
The thermal shift assay was conducted on a LightCycler 480 sys-
tem (Roche) in 96-well microplates. To monitor protein unfolding
and record the melting temperature of EthR, the protein was
heated in the presence of the environmentally sensitive ﬂuorescent
dye Sypro orange (Invitrogen). The unfolding process exposes
hydrophobic regions of the protein and induces an increase in ﬂuo-
rescence of the dye. To prepare the microplate, 5 ll of the ligand at
60 lM in Tris buffer (50 mM Tris–HCl, 300 mM NaCl, pH 7.5) in the
presence of 3% Me2SO is introduced into the appropriate wells. The
ligand solution is replaced by a 3% Me2SO solution in EthR buffer
for the negative controls. The EthR/Sypro orange solution (10 ll)
is added to all the wells to reach a ﬁnal concentration of 20 lM
in ligand, 10 lM in EthR, 2.5 in Sypro orange, and 1% in Me2SO.
After centrifugation, an incubation time of 30 min is allowed be-
fore the analysis. The plate is heated from 37 to 85 C with a heat-
ing rate of 0.04 C/s. The ﬂuorescence intensity was measured at
465/510 nm. The ﬂuorescence imaging data obtained from the
LightCycler 480 were treated and analyzed with IGOR software.
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from the maxima.
Results
SPR signal of the EthR/ligand interaction
Developing an SPR assay to detect interactions between small
synthetic ligands and EthR on a Biacore 3000 was a real challenge
because of the molecular mass of the ligands (between 300 and
500 Da). According to the Rmax formula [14], 2000 RU (2000 pg/
mm2) of EthR was covalently immobilized on a CM5 sensor chip.
Assuming an expected binding ratio of 1 ligand per EthR monomer,
a maximum theoretical response of 28 RU would be expected using
a 350-Da ligand. In a ﬁrst attempt to monitor the ligand-binding
propensity of immobilized EthR, we used BDM41907, a ligand
known to inhibit with a high efﬁcacy the ﬁxation of the repressor
on its DNA operator (IC50 375 nM). Injected onto the sensor surface
functionalized with immobilized EthR, BDM41907 produced an
unexpected sensorgram composed exclusively of negative values.
However, except for this unanticipated negative proﬁle, the curve
showed a classical shape, characterized by a marked and rapid re-
sponse at the beginning of the injection, followed by a plateau
upon continuous injection, and ﬁnally the progressive recovering
of the initial baseline after injection (Fig. 1).
The SPR signal is speciﬁc for the ligand/EthR interaction and dose-
dependent
Injections with increasing concentrations of BDM41907 from
0.3 to 81 lM were tested. Results showed highly reproducible
dose-dependent negative responses leading to a bona ﬁde plateau,
suggesting that the observed signal, although negative, translates
interactions between EthR and BDM41907 (Fig. 1). To assess the
speciﬁcity of this interaction, we evaluated the capacity of
BDM41160, a chemical analogue of BDM41907 previously shown
to be inactive as an EthR inhibitor using the TSA or the ‘‘DNA–EthR’’
SPR method [5]. Serial injections of increasing concentrations ofBDM41160 (from 9 to 243 lM) produced no signiﬁcant positive
nor negative shift of the SPR signal (Fig. 2). In contrast, dose-depen-
dent negative SPR signals were again observed with the two other
well-characterized speciﬁc EthR inhibitors BDM31381 [7] and
BDM41906 [6] (Fig. 2).
In a recent work, we designed and characterized a variant of
EthR (EthRG106W) in which the replacement of glycine 106 by a
tryptophan was shown to induce a conformation closely related
to the conformations of a holo-protein. X-ray crystallography
indeed revealed EthRG106W as an apoprotein stabilized in a
liganded-like conformation. SPR experiments conﬁrmed that, de-
spite the absence of ligands bound in its pockets, EthRG106W is un-
able to bind its DNA operator. Finally, isothermal titration
calorimetry experiments conﬁrmed the inability of EthRG106W to
interact with synthetic ligands [11], which makes this variant an
ideal negative control for the present study. Interestingly, injection
of BDM41907 onto a CM5 chip coated with EthRG106W resulted in a
complete absence of SPR signal (Fig. 3).
Altogether, these data strengthened the idea that the SPR
dose-dependent negative signal observed with BDM41907 reveals
speciﬁc interactions with EthR.Inﬂuence of the analytical conditions on the negativity of the SPR
signal
To exclude a maximum of possible artifactual effects that could
have led to this unusual but speciﬁc negative SPR signal [15], we
conducted a series of tests, including the variation of the concen-
tration of the immobilized protein, the roles of Me2SO and buffer,
and the impact of dextran.
In the ﬁrst set of experiments, the protein density at the surface
of the chip was either reduced (1000 RU) or increased (4000, 7000,
10,000 RU) and BDM41907 was injected at the constant value of
9 lM (Fig. 4). The negative SPR signal was clearly dependent on
the quantity of immobilized protein, suggesting that the negative
signal is the consequence of interactions between EthR and
ligands.
Deliberate variations in Me2SO concentration between running
and sample buffers were then tested to evaluate the impact on the
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Fig.4. Variation of the negative SPR response with the amount of immobilized EthR. (A) Analysis of BDM41907 response after a 9 lM injection on 1000, 2000, 4000, 7000, and
10,000 RU of immobilized EthR. Analytical conditions: HBS-EP running buffer; ﬂow, 20 ll/min; injection time of 2 min. (B) Response of BDM41907 at the end of the injection
(RU) as a function of the amount of EthR immobilized on the CM5 sensor chip (RU).refractive index. Injections of buffer were ﬁrst performed without
ligand. The 0.2% difference in Me2SO concentration between the
mock sample (0.8%) and the running buffer (1%) had a visible im-
pact on the sensorgram (Fig. 5A). However, the correction using
reference subtraction (F2F1) drastically reduced this effect from
200 to 4 RU (Fig. 5B). Subsequently, solutions of BDM41907 in
which Me2SO concentration ranged from 0.8% to 1.2% were pre-
pared. These samples were injected on the EthR-bound chips ﬂo-
wed in a running buffer containing 1% Me2SO. Classical reference
subtraction applied to the various BDM41907 injections almost
completely eliminated differences in the response level. Moreover,
reproducible signals of the 9 lM ligand injections were obtained
despite various differences between the Me2SO concentrations in
the running buffer versus in the sample buffer (Fig. 5C).
It has been shown that variations in Me2SO concentration can
occasionally give rise to large and rapid shifts in refractive index
during injection and thus can induce analytical artifacts [16]. Our
results revealed no such injection artifacts, suggesting that the
negative signal observed upon interaction between EthR and its
ligands cannot be attributed to the slight variations in Me2SO
concentration that may occur in the experiment.To fully rule out any possible inﬂuence of the Me2SO in the re-
corded negative signal, we used BDM41906, which shows a solu-
bility higher than 1 mM in phosphate-buffered saline, to perform
the experiment in the absence of Me2SO. BDM41906 as a powder
was solubilized at 100 lM directly in HBS-EP buffer (HBS-EP-no
Me2SO) (10 mM Hepes, 150 mM NaCl, 0.005% surfactant P20,
3 mM EDTA). The binding experiment between BDM41906 and
EthR was performed on a CM5 sensor functionalized with 4000
RU of EthRG106W on the reference ﬂow cell (F1) and with the equiv-
alent amount of EthR on the analysis ﬂow cell (F2) in the presence
of the HBS-EP-no Me2SO running buffer. BDM41906 was injected
at concentrations ranging from 0.3 to 100 lM on both channels.
As shown in Fig. 5D, a negative, dose-dependent signal was re-
corded upon injection of the Me2SO-free BDM41906 solution,
showing that the unconventional signal observed in our previous
experiments is unrelated to the presence of Me2SO.
It has been reported by some authors that a progressive loss of
matter during the run may sometimes result in a decrease in the
refractive index. Thus, we investigated the possibility that interac-
tion of EthR and dextran on the chip could decrease upon ligand
binding, which would take the protein away from the sensor chip
and explain the negative SPR signal. To challenge this hypothesis,
we ﬁrst analyzed a possible competition between free and
immobilized dextran. Injections of free dextran on the EthR sensor
surface were performed and no variation of the signal was
recorded. Then, we showed that injection of free dextran at various
concentrations (0.1, 1, and 5 mg/ml) did not modify the binding
signal observed with BDM41907. Altogether, these data showed
that dextran has no signiﬁcant afﬁnity for EthR, excluding its
capacity to bring the immobilized protein closer to the chip by
interacting with it (see sensorgrams in the Supplementary
material).
Alternatively, one can hypothesize the putative displacement
from the chip of a component other than EthR. As the SPR signal
returns to the initial value after injection phase, this would imply
that such loss would be systematically replaced by a component
present in the running buffer. To test this hypothesis, we replaced
the initial HBS-EP buffer (used for the continuous ﬂow and for the-500
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Fig.5. Inﬂuence of Me2SO variation on the negative SPR signal. (A) Sensorgrams of b
Sensorgrams of buffer injections containing 0.8 and 1% Me2SO on the analytical ﬂow cell
containing 0.8, 0.86, 0.93, 1, 1.06, 1.13, 1.2% Me2SO (sensorgrams obtained after dou
Sensorgrams of various concentrations of BDM41906 in Me2SO-free buffer (10 mM Hepsample preparation) by Tris buffer. Under these new conditions,
the previously observed negative signal was again obtained, thus
deﬁnitely ruling out the hypothesis of matter displacement.
In addition, the putative inﬂuence of electrostatic effect was
evaluated by testing a range of NaCl concentrations. Variation of
the SPR signal induced by the interactions of EthR and inhibitors
was not dependent on salt concentration in the tested range of
150–550 mM NaCl.
We ﬁnally tested whether this unconventional SPR signal can be
observed independent of the nature of the physicochemical link
that attaches EthR onto the chip. In the experiments described so
far, EthR had been covalently immobilized to CM5 sensor chips.
In this context, EthR was attached to the carboxymethylated dex-
tran matrix using the amine coupling chemical procedure de-
scribed under Materials and methods. We then tested whether
coupling EthR to the sensor chip using a noncovalent capture
method would still give negative SPR signal upon ligand binding400 500
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Fig. 5 (continued)to the protein. To this purpose, His-tagged EthR was captured in
the presence of Ni2+ ions on carboxymethylated dextran matrix
containing immobilized NTA (see Materials and methods). As pre-
viously shown for EthR-coated CM5 chips, injections of BDM41907
on NTA chips coated with His-tagged EthR produced a concentra-
tion dependent negative variation of the signal associated with
an equilibrium state (Fig. 7).
Dissociation constant determination
Whereas the physicochemical mechanisms withstanding the
negative SPR signal remain to be elucidated, this signal was shown
to be ligand-speciﬁc and dose-dependent. Other authors previ-
ously used such unconventional negative SPR curves to calculate
the protein–ligand dissociation constant [17–20]. We applied this
methodology to measure the dissociation constant values of a set
of well-characterized EthR ligands. In our experiments, the SPR sig-
nal recorded on EthR was systematically subtracted from the signalobtained on the reference EthRG106W-immobilized surface, which
drastically reduced all major injection artifacts. Association and
dissociation curves obtained after inversion of the negative sensor-
grams were ﬁtted using a kinetic Langmuir model 1:1 and led to an
acceptable ﬁt residue andv2 parameters (inferior to 5% of the Rmax)
(Fig. 6). The kinetic parameters were independent of the ﬂow rate,
indicating that the binding interaction between inhibitors and
EthR was not limited by a mass transport effect. KD values corre-
sponding to the association and dissociation curves obtained are
presented in Table 1. Moreover, no signiﬁcant variations in KD val-
ues were observed using various densities of protein captured on
the sensor chip (1000, 2000, and 4000 RU, Table 2). KD values ob-
tained from the ﬁtting procedure using the 1:1 binding Langmuir
model were compared with KD extrapolated from measures of
the resonance unit at the equilibrium state as a function of the
ligand concentration (KD at equilibrium, Table 2). Both methods re-
ported equivalent values, conﬁrming the validity of the ﬁtting
model chosen for KD determination.
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Fig.6. Inverted sensorgrams representative of BDM41907 binding with EthR. (A) Inverted sensorgrams obtained for BDM41907 binding at 0.1, 1, 3, 6, 9, 27, 81 lMwith EthR
immobilized on a CM5 surface (4000 RU); EthRG106W-immobilized surface was used as the reference ﬂow cell and HBS-EP as running buffer. Data were ﬁtted to the Langmuir
1:1 interaction model. (B) Plot of the residuals (differences between the data and the ﬁt).Comparison of afﬁnity data obtained by SPR and additional biological
parameters used to study EthR/ligand interaction (Tm, IC50)
In previous studies, we have described various methods that in-
form us directly or indirectly on the capacity of compounds to bind
to EthR. The ﬁrst developed method was a TSA revealing the capac-
ity of compounds to thermostabilize EthR upon binding [8,11,21].
A positive shift (DTm) in the melting temperature of the repressor
EthR in the presence of an inhibitor, relative to the Tm of the un-
bound protein, indicates that stabilization of the protein by the
compound has occurred. Independent studies have shown that
the stabilization of the protein due to ligand binding as revealed
by TSA is proportional to the afﬁnity and the concentration of
the ligand [22]. The KD’s deduced from the dose-dependent nega-
tive SPR signal for 13 synthetic ligands were compared with DTm
values obtained by TSA. Results presented in Table 3 show a good
correlation with an R2 of 0.84.
In parallel to the TSA, we previously designed a low-throughput
SPR test that measures the capacity of synthetic compounds to im-
pede the binding of EthR to its DNA operator [5–7]. Our effective
EthR inhibitors revealed typical IC50 in the micro- to the nanomolar
range. In Table 3, for 10 different ligands, we compared pKD ob-
tained by the ligand/EthR SPR test and pIC50 values deduced from
the EthR/DNA SPR test. The obtained correlation factor R2 of 0.81indicates that the afﬁnity of the ligands for EthR is correlated with
their ability to inhibit the DNA-binding function of EthR.
Discussion
The pivotal second-line anti-tuberculosis drug ethionamide
undergoes a process of bioactivation by the monooxygenase EthA
[4], the expression of which is negatively regulated by the TetR-like
repressor EthR in M. tuberculosis. It was demonstrated that the
basal level of EthR limits the bioactivation of ethionamide and,
consequently, participates in an innate form of resistance of M.
tuberculosis to this antibiotic. Previous works identiﬁed small
molecules that inhibit EthR and thus increase ethionamide efﬁcacy
[5–8,10].
In these previous studies we developed several biological and
biophysical assays to establish strong structure–activity relation-
ships. SPR was used to reveal the capacity of compounds to inhibit
EthR/DNA interaction in vitro [5–7]. It appeared reasonably predic-
tive of the efﬁcacy of the compounds in vivo. However, the DNA/
EthR SPR methodology reﬂects globally only the equilibrium that
encompasses both the binding of ligand to EthR and the binding
of EthR to its DNA operator. Although a thermal shift assay was
developed to quantify the thermostabilization of EthR by small
synthetic ligands [8,11], this test did not allow one to determine
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Table 1
Dissociation constants of EthR/ligand interactions measured by SPR.
Ligand 102 kon (M1 s1) 102 koff (s1) Rmax (RU) 106 KDa (M) v2
BDM44829 31.4 0.33 18.7 1.07 0.432
BDM44831 8.16 0.12 17.4 1.53 0.422
BDM41907 7.83 0.16 44.1 2.00 0.503
BDM43266 13.5 0.82 33.1 6.10 0.577
BDM41956 21.2 2.31 27.6 10.9 0.518
BDM41906 6.77 0.99 37.6 14.8 0.162
BDM44699 29.8 4.80 28.4 16.3 0.775
BDM31381 7.71 2.11 23.4 27.4 0.262
BDM31377 5.40 1.80 9.9 33.3 0.196
BDM41281 4.16 2.76 26.9 66.3 0.477
BDM41329 39.6 28.2 10.3 71.3 0.080
BDM41955 5.84 6.80 25.6 117 0.213
BDM31379 6.54 9.05 6.3 138 0.106
a Dissociation constants were measured on a CM5 sensor chip immobilized with 4000 RU of EthR. Sensorgrams were obtained after injection of at least six concentrations
for each ligand, inverted, and ﬁt to the Langmuir 1:1 interaction model. Analytical conditions: HBS-EP running buffer, 20 ll min1, EthRG106W as the reference ﬂow cell.binding constants. Albeit highly informative of the indirect activity
of the compounds at the various biological levels of the cell, allthese tests were unsuitable for ranking compounds strictly based
on their afﬁnity for the target.
Table 2
Comparison of KD measured by SPR.
BDM41907 BDM41906 BDM31381
106 KD eq (M) (2000 RU) 1.70 15.0 24.0
106 KD ﬁt (M) (1000 RU) 1.65 15.3 27.8
106 KD ﬁt (M) (2000 RU) 1.70 16.0 22.4
106 KD ﬁt (M) (4000 RU) 2.00 14.8 27.4
Repeatability (5) 106 KD (M) 1.58 ± 0.29 13.0 ± 2.1 25.8 ± 2.6
103 koff ﬁt (M) (1000 RU) 2.02 10.7 23.0
103 koff ﬁt (M) (2000 RU) 2.01 9.22 13
103 koff ﬁt (M) (4000 RU) 1.61 9.99 21.1
KD and kd values for BDM41907, BDM41906, and BDM31381 using 1000, 2000, or
4000 RU of captured EthR are shown in regular font. Comparisons of ﬁtting and
equilibrium processes for KD determination by SPR are shown in boldface.
Table 3
Comparison of the biological assays performed on EthR inhibitors.
Ligand pKD DTm (C)a pIC50b
BDM44829 5.97 13.0 —c
BDM44831 5.81 12.6 6.3
BDM41907 5.69 11.0 6.5
BDM43266 5.21 11.3 6.4
BDM41956 4.96 8.5 6.3
BDM41906 4.82 9.5 6.4
BDM44699 4.78 8.0 —c
BDM31381 4.56 9.8 5.8
BDM31377 4.47 9.0 5.8
BDM41281 4.17 8.5 5.7
BDM41329 4.14 6.0 5.3
BDM41955 3.93 6.3 —c
BDM31379 3.86 6.6 5.2
Correlation factor R2 0.8411 0.8087
a DTm represents the variation in the melting temperature of the repressor EthR
in the presence of inhibitor, relative to the Tm of the unbound protein alone.
b IC50 represents the concentration of ligand that inhibits 50% of the interaction of
EthR with its promoter.
c No value because of solubility problems.To overcome this limitation, we therefore developed a new SPR
assay based on the immobilization of the transcriptional repressor
on a CM5 sensor chip to determine KD values with our inhibitors.
All 13 tested compounds injected onto the EthR-coated chip pro-
duced unexpected SPR proﬁles characterized by negative values.
No signal was recorded when inactive analogues were tested, nor
when known EthR inhibitors were injected onto a chip functional-
ized with an EthR variant harboring a mutation known to block the
entrance of ligand into the binding pocket.
The KD values deduced from the dose–response curves obtained
with the studied ligands were compared with activities deduced
using two other assays. KD’s appear nicely correlated with DTm val-
ues obtained from thermal shift assays (R2 = 0.84), as well as with
IC50 values measured using an EthR/DNA SPR assay (R2 = 0.81). Two
conclusions emerge from these results. First, the relatively solid
correlation emerging from these pairwise comparisons reinforces
the evidence that the negative SPR signal recorded reﬂects speciﬁc
and quantitative afﬁnity between EthR and ligands. Second, an
important question concerning the inhibition of the DNA-binding
properties of EthR was about the relationship between the afﬁnity
of ligands for EthR and their effect on the DNA binding. With the
actual assay, we have now demonstrated that the inhibition of
the DNA-binding function of EthR (IC50) by synthetic inhibitors is
directly correlated with their afﬁnity (KD) for EthR.
SPR techniques have been extensively used to detect interac-
tions between two biological objects [12], assuming that the de-
tected effect is due to refractive index changes mainly due to
mass changes. Nevertheless, a growing number of teams have re-
ported negative dose-dependent SPR signals [17–20] tentatively
attributed to structural changes in the receptor induced by smallligands or inhibitors. Our results revealed a good correlation be-
tween the observed negative, dose-dependent, SPR signal and the
binding of our ligands to EthR.
In this work, we have tempted to identify what could explain
such negative SPR signal. The inﬂuence of buffers, Me2SO, protein
concentrations, and electrostatic parameters has been carefully
examined and eventually ruled out, opening the hypothesis that
the observed negative signal may reﬂect the structural changes
resulting from the ligand/protein interaction. The structural
changes in EthR and other TetR-type regulators mainly involve
the two helix-turn-helix (HTH) motifs of the dimeric active protein
[23–27]. Here, we propose that the negative SPR signal recorded
for EthR upon ligand binding may be detected using a nonoriented
functionalization of EthR to the biosensor. Changes in protein con-
formation upon ligand binding do not systematically translate in
negative SPR signal [28]. One can imagine that a positive signal
can also result from such changes, but this signal would be masked
by what would be assigned to the change of mass on the chip. Var-
ious teams have observed equivalent negative SPR responses upon
protein/ligand interactions [17–20]. Although not yet fully charac-
terized and still under debate, this signal was hypothesized to re-
ﬂect major changes in protein conformation resulting from ligand
binding [18]. Crystallographic studies revealed that EthR is com-
posed of two symmetrical ligand-binding sites and two mobile
HTHmotifs. These motifs are submitted to major structural reorga-
nization upon ligand binding: whereas DNA architecture forces
HTH motifs to adopt approximately a 34-Å center-to-center dis-
tance, the structure of the liganded form of EthR revealed a 52-Å
center-to-center distance. Thus, the main structural modiﬁcation
endured by the protein upon ligand binding is of large amplitude
(more than 15 Å), highly polarized, and peripheral [23–27].
While the impact of the amplitude of the conformational
change in SPR signal is not easily measurable or predictable, the
detection of conformational changes by SPR could constitute an
unexpected powerful functional screening method for the identiﬁ-
cation of allosteric inhibitors. In radioactive binding assays, for in-
stance, small ligands that interact with the target are identiﬁed
regardless of their capacity to induce conformation changes. In
contrast, the negative SPR signal observed here informed us on
both the binding constants and the inhibitory activity of EthR syn-
thetic ligands, which opens new perspectives on the use of SPR to
identify inhibitors of transcriptional regulators or of any ligand-
dependent allosteric control of soluble proteins.
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